Search - tctmd.com

Displaying 61 - 80 of 243

Sort: Relevancy | Date

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

L.A. McKeown

May 22, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2023

Shelley Wood

April 28, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Opinion CV Team Dispatch

October 2022 News Roundup

L.A. McKeown

October 01, 2022

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

Todd Neale

September 01, 2022

News Conference News ESC 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Yael L. Maxwell

August 31, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

Presentation ESC 2022

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Presenter: Michelle L. O’Donoghue

August 29, 2022

Presentation ESC 2022

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Presenter: John Eikelboom

August 29, 2022

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Advertisement

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

TCTMD’s Top 10 Most Popular Stories for April 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

October 2022 News Roundup

CV Care Around Noncardiac Surgery: New ESC Guidelines

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content